Drugs that contain Teriflunomide

1. List of Aubagio drug patents

AUBAGIO's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6794410 SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Sep, 2026

(3 years from now)

US6794410

(Pediatric)

SANOFI AVENTIS US Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4′-trifluoromethylphenyl)-amide for treating multiple sclerosis
Mar, 2027

(3 years from now)

US8802735 SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Sep, 2030

(7 years from now)

US8802735

(Pediatric)

SANOFI AVENTIS US (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
Mar, 2031

(7 years from now)

US9186346 SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Feb, 2034

(10 years from now)

US9186346

(Pediatric)

SANOFI AVENTIS US Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
Aug, 2034

(11 years from now)

Exclusivity Exclusivity Expiration
M (M) Apr 30, 2024
Pediatric Exclusivity (PED) Oct 30, 2024

Market Authorisation Date: 12 September, 2012

Treatment: Treatment of patients with relapsing forms of multiple sclerosis; Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

How can I launch a generic of AUBAGIO before it's patent expiration?
More Information on Dosage

AUBAGIO family patents

17

United States

6

European Union

4

China

3

Peru

3

Israel

2

Portugal

2

Uruguay

2

Russia

2

Spain

2

Costa Rica

2

New Zealand

2

Argentina

2

Taiwan, Province of China

2

Hong Kong

2

Honduras

2

Canada

2

Cyprus

2

Slovenia

2

Ukraine

2

Chile

2

Australia

2

Denmark

1

United Kingdom

1

Germany

1

Malaysia

1

Panama

1

Guatemala

1

Jordan

1

Brazil

1

Croatia

1

Colombia

1

Dominican Republic

1

Austria

1

Mexico

1

Morocco

1

Korea, Republic of

1

Belgium

1

Tunisia

1

Nicaragua

1

Lithuania

1

Japan

1

Luxembourg

1

Hungary

1

ME

1

Poland

1

Ecuador

1

RS

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in